-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Data show that since April, insurance institutions have investigated A-share listed companies 1,982 times, nearly doubling from the same period last ye.
Among them, the pharmaceutical and biological sector has attracted much attention from insurance fun.
In terms of individual stocks, the pharmaceutical stocks that insurance capital pays high attention to include Mindray Medical and Junshi Biotechnolo.
Judging from the pharmaceutical stocks surveyed by a single insurance fund, different institutions have different preferenc.
For example, Guohua Life Insurance prefers Medicilon; Ping An Pension pays more attention to Tonghe Pharmaceutical; Taiping Pension focuses on Mindray Medical and so .
Mindray Medical, which is more concerned by insurance funds, belongs to the head enterprise of domestic medical devices, and has attracted the attention of various institutions in recent yea.
Statistics show that in the past two years, the number of institutions received by the company has exceeded 3,000, of which 593 institutions have conducted research on the company in just one month (2026-2026), including more than 100 insurance institutio.
During the survey, the agency mainly focused on the income brought by the new infrastructure to the company, the progress of overseas business, how to deal with the changes brought about by the accelerated promotion of the DRG/DIP payment system, the company's strategy for dealing with the high-quality development of public hospitals, and how to deal with international expansion challenges, e.
Among them, in response to the changes brought about by the accelerated promotion of the DRG/DIP payment system, the company stated that it has adopted three strategies: First, in terms of helping hospitals to improve quality and efficiency, provide overall solutions and the "Sanrui" IT interconnection solution to help Medical institutions improve their ability to treat difficult and critical illnesses, and provide more customized medical services to help them improve the level of diagnosis and treatment; secondly, focusing on themes such as medical insurance payment reform, hospital management, and discipline construction, the company will organize hospital managers at all levels in 202 Participate in more than 100 learning and exchange activities of various types, covering nearly 2,000 hospitals in 31 provinces, municipalities and autonomous regions; thirdly, cooperate closely with hospitals and scientific research institutes, complement each other's advantages, participate in scientific research, and jointly solve major clinical problems and challenges , and by carrying out management and professional training courses, e.
, to improve the ability level of all kinds of talen.
In addition, in terms of overseas business, the company said that the company will usher in better development opportunities in the international market in the future, especially in developing countries with faster market grow.
The company will continue to increase marketing investment in developing countries, promote more and deeper localization strategies, and lay a solid foundation for the growth of developing countri.
From the perspective of production lines, the company will further promote the global manufacturing of IVD business and the layout of warehouse network systems, in order to achieve accelerated breakthroughs in high-end hospitals and large chain laboratori.
As far as Mindray Medical's financial report data is concerned, in 2021, the group's total revenue reached 227 billion yuan, a year-on-year increase of 22%; the net profit attributable to the parent was 00 billion yuan, a year-on-year increase of 2
In the first quarter of 2022, the group's total revenue reached 94 billion yuan, a year-on-year increase of 21%; net profit attributable to the parent company was 11 billion yuan, a year-on-year increase of 2
From the perspective of R&D investment, Mindray Medical's R&D investment in 2021 will be 73 billion yuan, a year-on-year increase of 3
In the first quarter of 2022, R&D investment was 740 million yuan, accounting for 17% of operating inco.
Under the condition of continuing to ensure high R&D investment, the company has continuously enriched products and continued to iterate technology, especially in high-end breakthroug.
A number of institutions believe that the current A-share market policies, valuations, funds and other indicators show some characteristics of the bottom, and they already have mid-line value, and it is recommended to deploy on di.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, the pharmaceutical and biological sector has attracted much attention from insurance fun.
In terms of individual stocks, the pharmaceutical stocks that insurance capital pays high attention to include Mindray Medical and Junshi Biotechnolo.
Judging from the pharmaceutical stocks surveyed by a single insurance fund, different institutions have different preferenc.
For example, Guohua Life Insurance prefers Medicilon; Ping An Pension pays more attention to Tonghe Pharmaceutical; Taiping Pension focuses on Mindray Medical and so .
Mindray Medical, which is more concerned by insurance funds, belongs to the head enterprise of domestic medical devices, and has attracted the attention of various institutions in recent yea.
Statistics show that in the past two years, the number of institutions received by the company has exceeded 3,000, of which 593 institutions have conducted research on the company in just one month (2026-2026), including more than 100 insurance institutio.
During the survey, the agency mainly focused on the income brought by the new infrastructure to the company, the progress of overseas business, how to deal with the changes brought about by the accelerated promotion of the DRG/DIP payment system, the company's strategy for dealing with the high-quality development of public hospitals, and how to deal with international expansion challenges, e.
Among them, in response to the changes brought about by the accelerated promotion of the DRG/DIP payment system, the company stated that it has adopted three strategies: First, in terms of helping hospitals to improve quality and efficiency, provide overall solutions and the "Sanrui" IT interconnection solution to help Medical institutions improve their ability to treat difficult and critical illnesses, and provide more customized medical services to help them improve the level of diagnosis and treatment; secondly, focusing on themes such as medical insurance payment reform, hospital management, and discipline construction, the company will organize hospital managers at all levels in 202 Participate in more than 100 learning and exchange activities of various types, covering nearly 2,000 hospitals in 31 provinces, municipalities and autonomous regions; thirdly, cooperate closely with hospitals and scientific research institutes, complement each other's advantages, participate in scientific research, and jointly solve major clinical problems and challenges , and by carrying out management and professional training courses, e.
, to improve the ability level of all kinds of talen.
In addition, in terms of overseas business, the company said that the company will usher in better development opportunities in the international market in the future, especially in developing countries with faster market grow.
The company will continue to increase marketing investment in developing countries, promote more and deeper localization strategies, and lay a solid foundation for the growth of developing countri.
From the perspective of production lines, the company will further promote the global manufacturing of IVD business and the layout of warehouse network systems, in order to achieve accelerated breakthroughs in high-end hospitals and large chain laboratori.
As far as Mindray Medical's financial report data is concerned, in 2021, the group's total revenue reached 227 billion yuan, a year-on-year increase of 22%; the net profit attributable to the parent was 00 billion yuan, a year-on-year increase of 2
In the first quarter of 2022, the group's total revenue reached 94 billion yuan, a year-on-year increase of 21%; net profit attributable to the parent company was 11 billion yuan, a year-on-year increase of 2
From the perspective of R&D investment, Mindray Medical's R&D investment in 2021 will be 73 billion yuan, a year-on-year increase of 3
In the first quarter of 2022, R&D investment was 740 million yuan, accounting for 17% of operating inco.
Under the condition of continuing to ensure high R&D investment, the company has continuously enriched products and continued to iterate technology, especially in high-end breakthroug.
A number of institutions believe that the current A-share market policies, valuations, funds and other indicators show some characteristics of the bottom, and they already have mid-line value, and it is recommended to deploy on di.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
